A lot of inputs, both monetary and calendar, go into your cotton crop each year. Today we’re focusing in on making the most of those investments during cotton defoliation with Davis Durham, Helena Agri-Enterprises.
SCHLIEREN, Switzerland, October 09, 2023 LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr
Adjuvant therapy, instead of just surgery alone, for early-stage non-small-cell lung cancer (NSCLC) after surgery incurs lower medical costs than surgery alone.
GSK's Arexvy vaccine for RSV can remain effective against a range of variants and produces strong antibody responses against distinct viral strains.